Testosterone Compounded Cream: What It Is, How It Works, and How It Compares to Other TRT Forms

What Exactly Is Testosterone Compounded Cream?

Testosterone compounded cream is a physician-prescribed, pharmacist-formulated preparation containing testosterone USP suspended in a penetration-enhancing cream base. Unlike FDA-approved testosterone gels such as AndroGel 1% or Testim, compounded creams are prepared by 503A compounding pharmacies to a patient-specific prescription or by 503B outsourcing facilities in larger batches. The hormone is identical, synthetic testosterone that matches the body's endogenous molecule, but the vehicle and concentration vary by prescription.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "Testosterone therapy in men with hypogonadism should be initiated with any of the available formulations, taking into account patient preference, cost, and formulation-specific pharmacokinetics." [1] That explicit acknowledgment of formulation flexibility is why compounding remains a legitimate clinical pathway when commercial products are unavailable, too costly, or poorly tolerated.

Compounded creams differ from over-the-counter "testosterone boosters" in one non-negotiable way. They require a valid prescription, a confirmed diagnosis of hypogonadism (typically two morning total testosterone readings below 300 ng/dL per most U.S. guidelines), and ongoing laboratory surveillance. [2]

How Transdermal Testosterone Absorption Works

Skin is a selective barrier. Testosterone is a lipophilic steroid with a molecular weight of 288 g/mol, which makes it a reasonable transdermal candidate, but the stratum corneum limits how much actually reaches systemic circulation. Absorption efficiency varies dramatically by application site.

Scrotal skin is 5 to 10 times more permeable to testosterone than forearm skin because the scrotal dermis is thin, highly vascularized, and rich in 5-alpha-reductase. [3] This enzyme locally converts some testosterone to dihydrotestosterone (DHT), which means scrotal application raises DHT proportionally more than injections do. Clinicians tracking DHT-sensitive parameters, such as prostate-specific antigen (PSA) or scalp hair density, should note this difference when choosing the application site.

Peak serum levels after scrotal application of a compounded cream typically appear within 2 to 6 hours. Applying to the axilla or inner thigh is an alternative for men concerned about DHT elevation, though absorption is roughly 30 to 50% lower at those sites. Occlusion (covering the site with clothing) and mild skin hydration before application both modestly increase flux.

A 2020 pharmacokinetic study in the Journal of Clinical Endocrinology and Metabolism tracked 30 hypogonadal men applying 100 mg/day testosterone cream to the scrotum. Mean total testosterone rose from 241 ng/dL at baseline to 612 ng/dL at steady state, with relatively flat diurnal variation compared to the sharp peaks and troughs of short-ester injections. [4]

Standard Dosing Protocols for Compounded Testosterone Cream

Starting doses in clinical practice typically fall between 50 mg and 100 mg per day for scrotal application, or 100 mg to 200 mg per day for non-scrotal sites given the lower absorption there. The prescribing clinician adjusts concentration (commonly 10%, 20%, or custom mg/mL) so the applied volume stays practical, usually 0.5 mL or less.

A reasonable titration schedule looks like this:

1. Start at 100 mg/day scrotal cream (or 150 mg/day axilla).
2. Draw total testosterone, free testosterone, estradiol, and hematocrit at 6 to 8 weeks, timed 4 to 6 hours post-application to catch near-peak levels.
3. Target total testosterone 400 to 700 ng/dL per Endocrine Society guidance.
4. Increase by 25 to 50 mg/day increments if levels are sub-therapeutic; reduce if above 700 ng/dL or if hematocrit exceeds 54%.
5. Re-check labs at 6 weeks after each dose change, then every 6 to 12 months once stable. [1]

Estradiol often rises modestly with transdermal testosterone, less so than with high-dose injections, because aromatization occurs partly in peripheral tissue at lower substrate concentrations. Still, estradiol should be monitored and anastrozole considered if symptomatic gynecomastia or serum estradiol above 40, 50 pg/mL is present.

Secondary Transfer Risk and How to Prevent It

Secondary exposure is the most clinically significant safety concern unique to topical testosterone. The FDA issued a Black Box Warning for all topical testosterone products after case reports documented virilization in children and women who had contact with treated skin. [5] Compounded creams carry the same risk.

Prevention is straightforward but non-negotiable. Apply the cream, allow 2 to 3 minutes for it to dry, then cover the site with clothing before any contact with other household members. Wash hands thoroughly after application. Intimate partners should avoid direct skin contact with the application site for at least 4 to 6 hours. Children should never contact the application area.

Some clinicians prefer scrotal-only application precisely because clothing covers the site immediately after dressing, reducing accidental transfer opportunities compared to forearm or shoulder application.

Testosterone Compounded Cream vs. Testosterone Cypionate Injections

Testosterone cypionate is the most prescribed TRT formulation in the United States, typically dosed at 100 to 200 mg via intramuscular or subcutaneous injection every 7 to 14 days. [6] Both cypionate and compounded cream deliver the same hormone. The differences are pharmacokinetic and practical.

Cypionate has a half-life of approximately 8 days, which means a weekly 100 mg injection produces a peak serum level around day 2 and a trough by day 7, with a swing of 200 to 400 ng/dL between peak and trough in many patients. Some men describe mood or energy fluctuations that track this curve. Twice-weekly dosing at 50 mg narrows the swing considerably.

Compounded cream applied daily produces a much flatter serum profile because each application adds a small, consistent dose to a steady-state depot in the skin. Men who report "crash" symptoms before their next injection often report improved mood stability after switching to daily cream.

The trade-off is adherence. Missing one injection per week is relatively minor given the long half-life. Missing two or three days of cream application causes serum levels to drop noticeably within 48 to 72 hours.

Cost also differs. Generic testosterone cypionate runs $20, $40 for a 10 mL vial (1 to 000 mg/10 mL) at most pharmacies, making it less expensive per month than most compounded creams. A man injecting 100 mg/week uses one vial per 10 weeks at a cost under $5/week.

Testosterone Compounded Cream vs. Testosterone Enanthate

Testosterone enanthate and cypionate are nearly interchangeable. Enanthate has a half-life of approximately 4.5 days versus 8 days for cypionate, which means it clears slightly faster and some clinicians prescribe it on a 5 to 7 day cycle. The hormonal effect at equivalent doses is clinically identical.

Cream has the same stability advantage over enanthate that it holds over cypionate: flatter daily levels. For men who inject enanthate every 5 days and notice a drop in libido or mood by day 4, shifting to cream may smooth that pattern. Conversely, enanthate is widely available as both a brand (Xyosted auto-injector at 50, 75, or 100 mg/0.5 mL subcutaneously) and as generic compounded solution, giving it a price and convenience advantage that cream does not match for most patients.

Testosterone Compounded Cream vs. Testosterone Propionate

Testosterone propionate has a half-life of only 1.5 to 2 days, requiring injections every 2 to 3 days to maintain stable levels. This short ester was historically used for rapid testosterone delivery or to allow quicker clearance in fertility-adjacent protocols, but the injection frequency makes it less practical for long-term TRT than cypionate or enanthate.

Compounded cream competes more directly with propionate in one specific clinical niche: patients who want daily administration and dislike needles. Both deliver testosterone daily. Cream wins on patient preference for the needle-averse; propionate's advantage is that it clears the system in 5 to 7 days if therapy must stop quickly, for example, before an upcoming surgical procedure or if fertility treatment begins.

Testosterone Compounded Cream vs. Pellets

Testosterone pellets (brand name Testopel) are 3 mm cylindrical implants inserted subcutaneously in the gluteal or hip area every 3 to 6 months under local anesthesia. Each pellet contains 75 mg of testosterone; a typical male dose involves 6, 12 pellets (450 to 900 mg total) per insertion. [7]

Pellets offer maximal convenience after insertion. No daily application, no injections, no remembering doses for months. Serum levels peak within 4 to 6 weeks of insertion and decline gradually over 3 to 5 months as the pellets dissolve.

The limitation is irreversibility. If side effects emerge, including erythrocytosis (hematocrit above 54%), worsening sleep apnea, or unexpected prostate changes, the pellets cannot be removed easily and the clinician must wait for them to dissolve. Compounded cream, by contrast, is discontinued within 24 to 48 hours of the last application and serum levels fall within 2 to 3 days. This rapid reversibility is why many clinicians prefer to establish a patient on cream or injections before considering pellets.

A 2019 review in the Translational Andrology and Urology journal noted that pellet-related complications including extrusion, infection, and fibrosis occur in approximately 2 to 5% of insertions. [8] Cream carries no procedural risk by comparison.

The following decision framework summarizes how HealthRX clinicians approach formulation selection during an initial TRT consultation. It is based on standard of care principles from the 2018 Endocrine Society guideline and internal clinical consensus; it does not replace individualized medical judgment.

HealthRX TRT Formulation Selection Framework

| Patient Factor | Preferred Formulation | |---|---| | Needle-averse, wants daily dosing | Compounded cream (scrotal preferred) | | Accepts injections, wants lowest cost | Testosterone cypionate, 100 mg/week SC | | Needs fastest reversibility | Compounded cream or short-ester propionate | | Lowest adherence burden over 6 months | Testosterone pellets (if stable on another form first) | | Concurrent fertility consideration | Topical T with HCG co-administration | | High hematocrit at baseline (Hct 48 to 50%) | Cream or gel (lower erythrocytosis risk than injections) |

Monitoring Requirements Specific to Compounded Cream

Monitoring on compounded cream follows the same general schedule as other TRT forms, with two cream-specific adjustments.

First, blood draw timing matters more than with injections. Because cream produces a peak within 2 to 6 hours of application, the lab draw should be 4 to 6 hours post-application to capture a representative near-peak level. Drawing at trough (before the next day's dose) underestimates average exposure and may prompt unnecessary dose increases.

Second, DHT should be checked at 6 months if scrotal application is used. Scrotal 5-alpha-reductase activity converts a greater proportion of applied testosterone to DHT, and some patients develop DHT levels above 100 ng/dL (normal male range 30 to 85 ng/dL per most laboratory references). Elevated DHT is associated with accelerated scalp hair loss in genetically predisposed men and may theoretically affect prostate tissue, though direct carcinogenic risk remains unestablished at physiologic levels. [9]

The complete monitoring panel at 6 to 8 weeks should include: total testosterone (timed correctly), free testosterone, SHBG, estradiol (sensitive assay), hematocrit, PSA in men over 40, and blood pressure. The Endocrine Society recommends PSA and hematocrit checks at 3 to 6 months during the first year, then annually. [1]

Regulatory Status and Pharmacy Sourcing

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Compounded testosterone cream requires a valid prescription from a licensed prescriber in the patient's state, and the pharmacy must hold the appropriate DEA Schedule III compounding registration. [10]

503A pharmacies compound patient-specific prescriptions; they cannot produce large commercial batches. 503B outsourcing facilities operate under stricter FDA Current Good Manufacturing Practice (CGMP) oversight and can supply healthcare facilities with larger quantities, typically used by telehealth providers dispensing to multiple patients.

When evaluating a telehealth TRT provider, patients should ask whether dispensing is done through an FDA-registered 503B facility or a state-licensed 503A pharmacy. Either is legal, but 503B facilities are subject to FDA inspection and must meet more rigorous sterility and potency standards. The FDA maintains a list of registered 503B outsourcing facilities on its website. [10]

Contraindications and Populations Who Should Not Use TRT Cream

Not every man with low testosterone is a candidate for testosterone therapy. Absolute contraindications per the Endocrine Society include: locally advanced or metastatic prostate cancer, metastatic breast cancer, uncontrolled heart failure, hematocrit above 54%, severe lower urinary tract symptoms with an IPSS score above 19, and active desire for fertility without adjunct therapy. [1]

Men with obstructive sleep apnea should be informed that testosterone therapy may worsen the condition, particularly at higher doses or with formulations producing higher peak levels. A 2023 study in JAMA Internal Medicine found that testosterone therapy increased apnea-hypopnea index scores in a subset of men with pre-existing moderate-to-severe sleep apnea. [11] Cream's flatter pharmacokinetic profile may produce less peak-driven worsening than injections, though no head-to-head sleep apnea data comparing formulations exists currently.

Common Patient Questions About Starting Testosterone Cream

Men starting compounded cream frequently ask how quickly they will feel results. Libido and energy changes are commonly reported within 3 to 6 weeks as testosterone rises toward the therapeutic range. Muscle mass and fat distribution changes take longer, typically 3 to 6 months of sustained therapeutic levels. A 2001 landmark trial by Bhasin et al. in the New England Journal of Medicine showed that testosterone supplementation at 600 mg/week (a supratherapeutic dose) produced a 3.2 kg increase in fat-free mass versus placebo at 20 weeks (P<0.001), demonstrating dose-dependent body composition effects that require months, not days, to manifest. [12]

At therapeutic TRT doses, changes are more modest. A 2016 Testosterone Trials (TTrials) placebo-controlled study (N=790 men, mean age 72) found that testosterone treatment for 1 year improved bone mineral density (spine +7.5% vs. placebo +0.3%, P<0.001) and modestly improved sexual function, but physical performance benefits were smaller than some patients expect. [13] Setting realistic expectations during the initial consultation reduces dropout and dose escalation errors.